Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone.

Saved in:

Bibliographic Details
Title:	Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone.
Authors:	Salvi, S¹, Casadio, V¹, Conteduca, V², Burgio, S L², Menna, C², Bianchi, E², Rossi, L², Carretta, E³, Masini, C⁴, Amadori, D², Calistri, D¹, Attard, G⁵, De Giorgi, U²
Source:	British Journal of Cancer. 5/12/2015, Vol. 112 Issue 10, p1717-1724. 8p. 2 Charts, 3 Graphs.
Database:	Academic Search Ultimate

Description
ISSN:	00070920
DOI:	10.1038/bjc.2015.128